button_search2

Tumor

Disclaimer
Copyright 2007
Eigenbrodt / Mazurek
Webdesign and
Webserver by
onSite

Combination of Tumor M2-PK with S100-beta

Combination of plasma Tumor M2-PK and serum S100-beta
determinations improves estimation of prognosis in melanoma.

marker combination

|
|

probability of overall survival
14 month after blood withdrawal

____________________________________________________________

S100-β ≤ 0.12 µg/ml
Tumor M2-PK ≤ 15 U/ml

S100-β ≤ 0.12 µg/ml
Tumor M2-PK > 15 U/ml

S100-β > 0.12 µg/ml
Tumor M2-PK ≤ 15 U/ml

S100-β > 0.12 µg/ml
Tumor M2-PK > 15 U/ml

|
|
|
|
|
|
|
|
|
|
|
|
|

0.98 ( n = 204)

0.95 ( n = 36)

0.58 ( n = 39)

0.27 ( n = 21)

Tumor M2-PK concentrations were measured in EDTA plasma with a sandwich ELISA from ScheBo Biotech AG Giessen, Germany.

S100-beta concentrations were measured in serum with a sandwich immunoluminometric assay (LIA-mat Sangtec 100) from Sangtec Medical, Bromma, Sweden).

Tumor M2-PK and S100-beta measurements: Selma Ugurel

References

Tumor M2-PK: correlations in melanoma

Metabolic tools for tumor diagnosis

Pyruvate kinase isoenzymes: M2-PK

[Home] [Overview] [Glycolysis] [Glutaminolysis] [Nucleogenesis] [Serinolysis] [Lipogenesis] [tumor_metabolome_key_metabolites] [Nutrients] [Oncoproteins] [tumor_diagnosis] [Animations]